0001493152-26-022534
SEC filingKopin's Q1 FY26 revenues were flat year-over-year, but product sales declined sharply and negative product gross margin drove a wider operating loss, offset by non-operating gains and grant income.
Kopin reported total revenues of $10.55M for the three months ended March 28, 2026, essentially flat compared to $10.54M in the same period last year. However, revenue composition shifted dramatically: net product revenues dropped 41% to $5.42M from $9.23M, driven primarily by lower production volumes of thermal weapon sight components and liquid crystal displays. This decline was offset by $3.44M in grant income (new government MicroLED program) and $0.33M in collaboration arrangement income from the Theon partnership, both absent in the prior year.
Cost of product revenues was $5.61M, resulting in a negative 3% product gross margin compared to 17% in Q1 2025. Management attributed this to "reduced production efficiency and lower production volume" and characterized it as an uncommon occurrence.
Total operating expenses rose 14.5% to $16.54M. Funded R&D expense surged from $0.64M to $3.81M due to grant-related development costs, while internal R&D decreased. SG&A increased 28% to $6.02M due to higher professional fees and accrued performance-based compensation. Consequently, operating loss widened to $(5.99M) from $(3.91M).
Non-operating income of $2.29M (vs $0.85M) included a $2.3M gain on equity investments, partially stemming from fair value increases in equity-method investments (Kopin Europe Ltd.) and publicly traded Global Communication Semiconductors. Net loss attributable to common stockholders was $(3.79M) or $(0.02) per share, compared to $(3.11M) and $(0.02) per share in the prior year.
Total assets decreased to $102.4M from $108.4M at fiscal year-end 2025, driven by a $7.3M reduction in accounts receivable (from $10.7M to $3.4M) and a $2.2M decline in cash and cash equivalents. Restricted cash remained steady at $25.3M, mainly tied to the litigation bond.
Working capital was $50.9M (current assets $82.4M less current liabilities $31.5M), down from $57.8M at year-end. Total stockholders' equity fell to $60.8M from $64.1M, impacted by the net loss and preferred stock dividends.
The company held $34.1M in unrestricted cash, which management believes is sufficient to fund operations for at least 12 months, with liquidity projected into Q3 2027. However, the $19.7M BlueRadios judgment (under appeal) represents a material contingent liability, secured by a $24.2M bond.
Operating cash flow improved to a use of $(0.81M) from $(3.41M) in the prior year, reflecting strong working capital generated by a $7.2M reduction in receivables. Capital expenditures increased to $1.30M (from $0.50M), resulting in negative free cash flow of $(2.11M). No debt was raised or repaid; financing activities consisted solely of $29,167 in preferred stock dividends paid.
Management noted that the negative product margin was an "uncommon occurrence" and expects "a combination of customer price increases on follow-on purchase orders and improvements in production efficiency will result in positive product margins in future periods." Funded R&D will continue under the government grant and Theon collaboration. SG&A is expected to remain elevated due to professional fees and litigation costs.
The company raised $38.1M in a PIPE in September 2025 and $15M from Theon in October 2025, providing a solid cash position. No formal revenue or earnings guidance was provided. Management reiterated that they monitor capital markets for potential further equity raises if needed.